Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Key facts
- Who runs it
- Ohio State University Comprehensive Cancer Center
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 31 Dec 2025
- Ended
- 31 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Capecitabine
- Docetaxel
- Fluorouracil
- Leucovorin
- Oxaliplatin
- Radiation Therapy
- Surgical Procedure
- Record updated
- 7 February 2025
- Why it stopped
- PI Decision
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Patients with histologically proven, cT2N0-T4aN3M0 (TNM 8th edition), gastric or Siewert II-III GEJ adenocarcinoma
- Evaluation with endoscopic ultrasound (EUS) and staging laparoscopy prior to enrollment is strongly recommended
- Patient should be a candidate for neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) or fluorouracil and oxaliplatin (FOLFOX)
- Patients should be >= 18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Patient should be eligible for surgical intervention
- T1 N0 disease (assessed by endoscopic ultrasound)
Who cannot take part
- Solitary functioning kidney within the potential radiation field
- Evidence of distant metastatic disease
- Peripheral polyneuropathy > National Cancer Institute (NCI) grade II
What happens in this trial
What the trial wants to find out
This phase I trial tests the safety, side effects studies chemotherapy followed by chemotherapy at the same time as radiation therapy (chemoradiation) before surgery (neoadjuvant) in treating patients with stage gastric (stomach) or gastroesophageal junction cancer . Chemotherapy drugs, such as docetaxel, oxaliplatin , leucovorin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy and chemoradiation before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.
The group in the trial
- Treatment (chemotherapy, chemoradiation, surgery)Treatment being tested
NEOADJUVANT CHEMOTHERAPY: Patients receive FLOT chemotherapy consisting of docetaxel intravenously (IV) , oxaliplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on day 1 or FOLFOX chemotherapy consisting of oxaliplatin IV and leucovorin IV, and fluorouracil IV continuously over 24 hours on days 1 and 2. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. NEOADJUVANT CHEMORADIATION: Within 4 weeks after completing neoadjuvant chemotherapy, patients undergo radiation therapy in 25 fractions over 5 weeks. Patients also receive either fluorouracil IV continuously for 24 hours on days 1-5 or capecitabine orally (PO) twice daily (BID) on days 1-5. Cycles repeat weekly for 5 weeks in the absence of disease progression or unacceptable toxicity. SURGERY: Within 4-8 weeks after neoadjuvant chemoradiation, patients undergo surgical resection according to tumor location and per surgeon expertise.
Treatment: Capecitabine, Docetaxel, Fluorouracil, Leucovorin, Oxaliplatin, Radiation Therapy, and Surgical Procedure
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Total Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction (GEJ) and Gastric Cancers: A Pilot Trial
- Record updated
- 7 February 2025